Medicare to fully cover lung cancer biomarker testing starting 2027.
This bill mandates that the Medicare program must fully cover advanced biomarker testing for individuals diagnosed with lung cancer, effective January 1, 2027. This change ensures that Medicare beneficiaries will face zero out-of-pocket costs for these precise diagnostic tests, which are essential for determining personalized treatment strategies. The goal is to improve access to cutting-edge cancer care.
Key points
Medicare coverage is required for lung cancer biomarker testing (analyzing genes, proteins, or molecules).
Beneficiaries will pay nothing; the coverage rate is 100% of the reasonable charges for the testing.
The new coverage requirement takes effect on January 1, 2027.
Status:
Introduced
Civic Will
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.